A population based cohort study to assess the safety of pandemic influenza vaccine Focetria(®) in Emilia-Romagna region, Italy-Part Two

A two phases post authorization safety and effectiveness study of individuals vaccinated with the MF59-adjuvanted A/H1N1 influenza vaccine, Focetria(®) (Novartis Vaccines & Diagnostics, Siena, Italy), was conducted in Emilia-Romagna region, Italy during the 2009 A/H1N1 influenza pandemic. The second phase study aim was to detect short- and long-term adverse events of special interest (AESIs) following vaccination, and to measure vaccine effectiveness in term of hospital admissions.

Link al full text (se abilitati)
Vaccine, 2012 Aug 10. [Epub ahead of print]

[SINTESI]